# Phase 2 Study of WGI-0301 for Advanced HCC

> **NCT06309485** · PHASE2 · RECRUITING · sponsor: **Zhejiang Haichang Biotech Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** WGI-0301 at MTD/RP2D dose IV infusion, QW
- **DRUG:** WGI-0301 at MTD/RP2D -1 dose IV infusion, QW
- **DRUG:** Sorafenib 400 mg PO, BID continuously
- **DRUG:** Sorafenib 400 mg PO, BID

## Key facts

- **NCT ID:** NCT06309485
- **Lead sponsor:** Zhejiang Haichang Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06309485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06309485, "Phase 2 Study of WGI-0301 for Advanced HCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06309485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*